Oliver Jonas
This pilot study will assess the safety and feasibility of using an implantable microdevice to measure local intratumor response to chemotherapy and other clinically relevant drugs in malignant brain tumors. * The device involved in this study is called a microdevice. * The drugs used in this study will only include drugs already used systemically for the treatment of gliomas.
This research study is a Pilot Study, which is the first time investigators are examining this study device in brain tumors. The FDA (the U.S. Food and Drug Administration) has not approved the microdevice as a treatment for any disease. Investigators are studying the safety of the microdevice and the effects of different drugs for each specific tumor. Brain tumors are known to be very different from each other and respond differently to different drugs. It would be very helpful to find out what drugs have the best chance of working in each specific tumor. This research study involves drugs…
Inclusion Criteria: * Patients must have operable supratentorial tumor presumed to be WHO grade II-IV glioma (Astrocytoma, Oligodendroglioma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, or Glioblastoma) based on radiological evidence at MRI, where a gross total or partial surgical resection is intended. * Histological confirmation of WHO grade II-IV glioma at time of intraoperative frozen analysis (for newly diagnosed tumors). This is not necessary in cases where a histopathologic diagnosis is already available from prior surgeries/biopsies. * Participants must be 18 years of age or…
Placement of 1-3 microdevices (depending on the size of the tumor) approximately 3 days before tumor resection. The microdevices will dwell in the tumor tissue for a time window of approximately 3 days to allow time for the drug microdoses contained in the devices to diffuse into the tumor, and to allow time for tissue effects of the drugs to be measured. Drugs include: Temozolomide, Lomustine, Irinotecan, Carboplatin, Lapatinib, Niraparib, Osimertinib, Abemaciclib, and Everolimus, Nivolumab, Opdualag, Ipilimumab, Gabapentin, Perampanel, Tocilizumab, Meclofenamate, Bumetanide, Prochloperazine, Decitabine, PTC596, RNA-containing lipid nanoparticle (including compounds CL3, SCR and CL3\_a2), and Vortioxetine are released by the microdevice reservoirs. The drugs used in this study will include drugs already used systemically for the treatment of gliomas and investigational agents.
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.